Bora Pharmaceuticals Co (TPE:6472) EV-to-EBIT : 12.51 (As of May. 30, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Bora Pharmaceuticals Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bora Pharmaceuticals Co's Enterprise Value is NT$94,505 Mil. Bora Pharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was NT$7,557 Mil. Therefore, Bora Pharmaceuticals Co's EV-to-EBIT for today is 12.51.

The historical rank and industry rank for Bora Pharmaceuticals Co's EV-to-EBIT or its related term are showing as below:

TPE:6472' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.87 Med: 20.59 Max: 285.14
Current: 12.5

During the past 13 years, the highest EV-to-EBIT of Bora Pharmaceuticals Co was 285.14. The lowest was 6.87. And the median was 20.59.

TPE:6472's EV-to-EBIT is ranked better than
64.83% of 688 companies
in the Drug Manufacturers industry
Industry Median: 16.935 vs TPE:6472: 12.50

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bora Pharmaceuticals Co's Enterprise Value for the quarter that ended in Mar. 2025 was NT$84,499 Mil. Bora Pharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was NT$7,557 Mil. Bora Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 8.94%.

Bora Pharmaceuticals Co EV-to-EBIT Historical Data

The historical data trend for Bora Pharmaceuticals Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bora Pharmaceuticals Co EV-to-EBIT Chart

Bora Pharmaceuticals Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-EBIT

Get a 7-Day Free Trial

20.81

12.90

18.37

16.27

17.02

Bora Pharmaceuticals Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															18.42	22.37	17.08	17.02	11.18

Competitive Comparison of Bora Pharmaceuticals Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bora Pharmaceuticals Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bora Pharmaceuticals Co's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Bora Pharmaceuticals Co EV-to-EBIT Calculation

Bora Pharmaceuticals Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	94504.778	/	7557.094
	=	12.51

Bora Pharmaceuticals Co's current Enterprise Value is NT$94,505 Mil.
Bora Pharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$7,557 Mil.

Bora Pharmaceuticals Co (TPE:6472) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bora Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 )	=	EBIT	/	Enterprise Value (Q: Mar. 2025 )
	=	7557.094	/	84499.139
	=	8.94 %

Bora Pharmaceuticals Co's Enterprise Value for the quarter that ended in Mar. 2025 was NT$84,499 Mil.
Bora Pharmaceuticals Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$7,557 Mil.

Bora Pharmaceuticals Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bora Pharmaceuticals Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Bora Pharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bora Pharmaceuticals Co Ltd (TPE:6472) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 2, Aly. 36, Lane 26, Ruiguang Road, 6th Floor, Neihu District, Taipei, TWN, 114

Website

https://www.bora-corp.com

Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Commercial sales segment, Contract Development & Manufacturing Organization segment, and Other segment. The majority of revenue is derived from the Commercial sales segment. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.

Bora Pharmaceuticals Co Headlines

No Headlines